Can Aimovig (Erenumab) Cause Hair Loss?

Understanding Erenumab and Its Mechanism

Erenumab, marketed as Aimovig, represents a breakthrough in migraine prevention as the first FDA-approved CGRP (calcitonin gene-related peptide) receptor antagonist. Approved in 2018, this medication works by blocking CGRP receptors in the brain, reducing the frequency and severity of migraine episodes. The drug has helped millions of patients achieve better migraine control when traditional preventives have failed.

The mechanism behind Aimovig's effectiveness involves targeting specific pathways in migraine pathophysiology. By blocking CGRP receptors, erenumab interrupts the cascade of events that trigger migraine attacks. Understanding this targeted action helps explain why certain side effects, including potential impacts on hair health, may occur in some patients.

As with any medication that affects neurological pathways, erenumab can produce various side effects. While most patients tolerate the treatment well, reports of hair thinning and loss have emerged both during clinical trials and in post-marketing surveillance, prompting questions about the relationship between this migraine medication and hair-related changes.

Clinical Evidence on Hair Loss and Erenumab

Clinical trial data reveals that hair loss occurred in approximately 1-2% of patients receiving erenumab compared to less than 1% in placebo groups. While these numbers appear small, the statistical significance and temporal relationship suggest a genuine association between the medication and hair-related changes.

Post-marketing surveillance has provided additional insights into erenumab's effects on hair. Reports to the FDA's Adverse Event Reporting System (FAERS) have documented cases of diffuse hair thinning, increased hair shedding, and in some instances, more significant hair loss patterns. These reports often describe onset within 2-6 months of treatment initiation.

The mechanism behind erenumab-induced hair loss remains unclear, but researchers theorize it may involve disruption of hair follicle cycling or changes in scalp blood flow. Since CGRP plays roles beyond migraine pathophysiology, including potential effects on hair follicle biology, blocking these receptors might inadvertently impact normal hair growth patterns.

Types of Hair Loss Associated with Aimovig

Patients experiencing erenumab-related hair changes typically report diffuse thinning rather than localized bald patches. This pattern, known as telogen effluvium, involves increased shedding across the entire scalp, leading to overall hair volume reduction. Unlike androgenetic alopecia, which follows predictable patterns, drug-induced hair loss tends to be more uniform.

The timeline of hair loss development varies among patients. Some notice increased shedding within weeks of starting treatment, while others may not observe changes until several months later. The gradual nature of this side effect often makes it challenging to initially connect with medication use, particularly when other factors might contribute to hair health changes.

Severity ranges from mild thinning that may only be noticeable to the patient to more pronounced hair loss that becomes apparent to others. Most cases fall on the milder end of this spectrum, though individual responses vary significantly based on factors like baseline hair density and genetic predisposition.

Distinguishing Drug-Induced Hair Loss from Other Causes

Differentiating erenumab-related hair loss from other causes requires careful evaluation of timing and patterns. The hair connection between medication initiation and symptom onset provides the strongest clue, particularly when hair loss begins within months of starting treatment.

Other medications commonly cause hair thinning, making it essential to review all treatments when evaluating potential causes. Drug-induced hair thinning can result from various medication classes, including anticoagulants, antidepressants, and blood pressure medications. Patients taking multiple medications may experience cumulative effects on hair growth.

Medical conditions like thyroid disorders, nutritional deficiencies, and hormonal changes can also contribute to hair loss. Comprehensive evaluation often includes laboratory testing to rule out underlying medical causes while carefully reviewing the temporal relationship between medication changes and hair loss symptoms. This thorough approach helps ensure accurate diagnosis and appropriate treatment recommendations.

Managing Hair Loss While on Erenumab Treatment

For patients experiencing hair loss while taking Aimovig, treatment options focus on supporting hair regrowth and minimizing further loss. Topical minoxidil may help stimulate hair follicles and promote regrowth, though results vary among individuals. Nutritional support, including adequate protein, iron, and vitamins, provides the building blocks necessary for healthy hair growth.

Discontinuing erenumab often leads to hair regrowth, though the timeline varies considerably. Some patients notice improvement within 3-6 months, while others may require up to a year for significant regrowth. The decision to stop treatment involves weighing migraine control benefits against cosmetic concerns, requiring careful discussion with healthcare providers.

Balancing effective migraine prevention with quality of life concerns requires individualized approaches. Some patients choose to continue erenumab despite mild hair thinning if migraine control significantly improves their daily functioning. Others prioritize hair concerns and explore alternative treatments. Regular monitoring and open communication with healthcare providers ensures optimal decision-making throughout the treatment process.

Alternative Migraine Prevention Options

Patients concerned about erenumab's potential effects on hair have several alternative prevention options. Other CGRP inhibitors, including fremanezumab (Ajovy) and galcanezumab (Emgality), offer similar migraine prevention benefits but may have different side effect profiles. While these medications work through similar mechanisms, individual responses can vary significantly.

Traditional migraine preventives provide alternatives with different mechanisms and side effects. Beta-blockers like propranolol, anticonvulsants such as topiramate, and antidepressants including amitriptyline have established efficacy for migraine prevention. Each class carries unique benefits and risks that require consideration based on individual patient factors and comorbidities.

Doctronic's AI consultations have helped over 22 million patients navigate complex treatment decisions, with 99.2% treatment plan alignment with board-certified physicians. This level of clinical expertise proves invaluable when weighing treatment options and developing personalized migraine management strategies that address both efficacy and quality of life concerns.

The Bottom Line

While hair loss is an uncommon side effect of Aimovig, affecting only 1-2% of patients, it's important to weigh this risk against the medication's proven benefits for migraine prevention. Most hair loss cases are reversible after discontinuing treatment, and alternative migraine preventives are available for those concerned about this side effect. Working closely with your healthcare provider ensures you receive appropriate migraine management while addressing any cosmetic concerns. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.